/
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
Jazz Pharmaceuticals plc is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with rare disease often with limited or no therapeutic options.
$243.71
$6.97 (-2.78%)
EOD Sep 1, 2026
The business is unprofitable at the operating level (-10.08% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue grew 4.9%, steady but not accelerating. Margins contracted 27.7pp, which offsets some of the top-line progress.
ROIC dropped from 5.72% to -3.40%, capital efficiency is deteriorating. Operating margin contracted 27.7pp YoY, cost discipline may be slipping.
16.7x earnings, 10.6x FCF. Valuation is in a reasonable range. The main question is whether the business can re-accelerate or if current trajectory is already priced in.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$4.60B
▲ +4.9% YoY
Net Income (TTM)
$941M
▼ -163.6% YoY
Op. Margin
19.49%
▼ -27.7pp YoY
ROIC
7.41%
▼ -9.1pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$1.59B
▼ -4.5% YoY
Op. Cash Flow (TTM)
$1.66B
▼ -2.9% YoY
Net Debt
$2.78B
Cash & Equiv.
$1.62B
5Y CAGR: +12.5%
5Y CAGR: +8.0%
Continue Research
SourceComputed from the 10-Q filed 3 Aug 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 4 Aug 2026. How this is calculated.
Price from market data, last close as of 1 Sept 2026. Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically.
At a P/E of 16.7 and a price-to-free-cash-flow of 10.6, Jazz Pharmaceuticals (JAZZ) trades below a two-stage DCF intrinsic value of about $888.32 per share, so at $243.71 the stock looks undervalued (264.5% below estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Jazz Pharmaceuticals scores 63/100 on Intrinsiqq's quality scorecard (a solid business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about $888.32 per share for JAZZ, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around $666.24. At today's $243.71, that puts the stock about 264.5% below estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Jazz Pharmaceuticals scores 63 out of 100 on Intrinsiqq's quality score, a weighted blend of 8 metrics each scored 0 to 100, which makes it a solid business on these measures. Recent fundamentals include a 19.5% operating margin and a 7.4% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. JAZZ currently trades below its estimated intrinsic value and scores 63/100 on quality (solid). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.